ABSTRACT
Translational Relevance
GRB7 RNA expression was associated with a significantly increased risk of recurrence in operable triple negative breast cancer (TNBC) patients treated with adjuvant anthracycline chemotherapy in our analysis, and in external validation studies was associated with resistance to neoadjuvant anthracycline therapy but was not prognostic in operable TNBC patients who received no adjuvant therapy. GRB7 belongs to a small family of mammalian SH2 domain adapter proteins that are known to interact with a number of receptor tyrosine kinases and signaling molecules (including HER1, HER2, and ephrin receptors), with the integrin signaling pathway, and focal adhesion kinase (FAK). GRB7 shares sequence homology with the mig-10 gene of C. elegans, which is required for migration of embryonic neurons, suggesting an important role in cell motility. These findings suggest that high GRB7 expression has a role as a potential biomarker for resistance to anthracycline therapy and serve as a therapeutic target in
TNBC.
Research. TNBC is associated with a higher risk of distant recurrence, earlier time to recurrence, and worse prognosis after recurrence. 2, 3 About 80% of TNBC are characterized as being of a basal-like breast cancer genotype identified by gene expression profiling. 4, 5 , 6 A panel of antibodies which includes cytokeratin markers may more accurately classify basal subtypes than relying on ER, PR, and HER2/neu expression alone. 7, 8 Although inhibitors of poly (ADP-ribose) polymerase may hold promise 9 , therapeutic approaches are currently limited to cytotoxic chemotherapy In the current study that is the subject of this report, we evaluated gene expression patterns from tumors derived from a cohort of patients with stage I-III breast cancer treated with adjuvant doxorubicin-containing chemotherapy. In addition to performing gene expression profiling, we defined breast cancer subsets by standard IHC for ER, PR, and HER2/neu protein expression in a central laboratory. 10 We evaluated differences in gene expression patterns between triple negative disease and HR-positive, HER2/neu negative disease. We also performed an exploratory analysis evaluating the relationship between gene expression and recurrence within the triple negative group. Our objectives were to identify RNA expression biomarkers associated with recurrence within the TNBC group, and potential therapeutic targets for the TNBC group which may not have been previously recognized.
METHODS

Study Population and Treatment
The study utilized tumor specimens and clinical information from patients enrolled on trial E2197 (ClinicalTrials.gov identifier NCT00003519), coordinated by the Eastern Cooperative Oncology Group (ECOG), details of which have been reported elsewhere. 11 Briefly, patients were randomly assigned to receive four 3-week cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) or docetaxel 60 mg/m2 (AT). Methods for selection of cases included in the genomic analysis have been previously described 12 , and summarized in the CONSORT diagram shown in supplemental Figure 1 . The characteristics of the sample cohort were comparable to the excluded cohort, also as previously described. 12 The clinical protocol was approved by the institutional review boards of all participating institutions and was carried out in accordance with the Declaration of Helsinki, Food and Drug Administration Good Clinical Practices, and local ethical and legal requirements. The use of specimens for this project was approved the North American Intergroup Correlative Science Committee and by the Northwestern University Institutional Review Board (which oversees the ECOG 6 RNA expression levels were measured by real time reverse transcriptase polymerase chain reaction (RT-PCR) using gene-specific primers. 13 The panel of 374 genes was assembled by searching the published literature, genomic databases, pathway analysis, and microarray-based gene expression profiling experiments performed in fresh frozen tissue to identify genes likely to be associated with prognosis or response to chemotherapy, as previously reported.
.
A total of 246 cases were defined as having TNBC by IHC using the methods described above, of whom 15% had a recurrence. This cohort includes only one patient (who did not recur) whose tumor was HER2/neu positive by the Genomic Health RT-PCR assay (>/= 11.5 units), which has been found to exhibit 97% concordance with HER2/neu gene amplification by fluorescent in situ hybridization. 
Statistical analyses
The relationship between gene expression and recurrence was evaluated using weighted Cox proportional hazards model score tests used to rank genes by their individual significance for predicting recurrence risk as previously described.
14 Recurrence was defined as distant and/or local-regional recurrence of disease. Among the 59 recurrences, 39 were distant and 20 were local-regional. Adjusted p-values controlling the false discovery proportion (FDP) at ≤ 10% were computed using algorithm B* in Korn et al. 16 (using 500 permutations) and were applied in a 'step-down' fashion. 17 A weighted algorithms were used to correct for differential sampling of relapse and nonrelapse cases. 18 All p values are two-sided. Differences in gene expression were evaluated between the HR-negative (ie, triple negative; N=246) and HR-positive, HER2-negative groups (N=383) by a weighted t test. Pathway analysis was performed using Ingenuity Pathway Analysis Version 7.6 on the top 40 genes overexpressed in TNBC versus HR-positive, HER2-negative tumors.
External Validation
We evaluated the relationship between GRB7 expression and outcomes in several publicly available datasets, which used various methods to examine gene expression, including populations with operable disease 5, 19, 20 in which we evaluated the relationship between GRB7 expression and prognosis, and in two neaoadjuvant datasets in which we evaluated the relationship between GRB7 expression and response to anthracycline and taxane-containing neoadjuvant chemotherapy 21, 22 . From studies in which the depositing investigators had annotated their samples as "Basal-like" we used these For the neoadjuvant datasets, a major issue was the relative insensitivity of the Affymetrix probesets compared the sensitivity of the RT-PCR assay used in our analysis.
The RT-PCR assay for GRB7 detected differences across a 190-fold range among TNBC cases in our study, while the Affymetrix X3P probe used in the study by Bonnefoi et al had a dynamic range of 3-fold in the TNBC samples, and the Affymetrix U133A probe used in the. study by Tabchy et al had a dynamic range of only 5-fold. To try to understand the inefficiency of these probesets we used the Affy package of Bioconductor to extract the raw probe-level data from each microarray used in the Bonnefoi study.
This permitted us to individually analyze the signal values for each of the 11 probes that make up the GRB7 probeset across 160 microarrays. In general, the correlation coefficient between the individual probes and the aggregate value reported for GRB7 in each array was relatively good, with Pearson correlation coefficients ranging from 0.79 to 0.93. However, when we stratified the data by into ERBB2/GRB7 amplified (i.e. high GRB7 mRNA) and non-amplified (i.e. low GRB7 mRNA), an interesting difference emerged. For the high GRB7 expressors, the performance of the individual probes remained good, with Pearson Correlation coefficients ranging from 0.80 to 0.91).
However, in the low GRB7 expressors (of which the TNBC samples in this study are a substantial subgroup) the correlation between the individual GRB7 probes the overall value reported for the GRB7 probeset was significantly reduced, with Pearson's correlation coefficients ranging from -0.38 to 0.29). From this analysis, we concluded that although the GRB7 probeset on these arrays works very well when GRB7 mRNA is abundant, at lower GRB7 levels it suffers from a substantial amount of noise, resulting in a substantial loss of linearity. For this reason, our validation studies have not assumed that the signals in this range are drawn from a Gaussian distribution, and we have used the rank-based Mann-Whitney U-test to attempt to discern whether there are differences in outcome depending on GRB7 levels.
RESULTS
Characteristics of Triple Negative Population
The characteristics of patients with TNBC are shown in Table 1 . Most patients were 65 or younger (93%), had tumors with poor histologic grade (90%) that were associated with negative axillary lymph nodes (81%), and occurred in white subjects (87%). When compared with 60 patients who had HR-negative, HER2-positive disease, patients with TNBC were younger (41% vs. 27% less than 46, p=0.04) and more likely to have negative axillary nodes (81% vs. 66%, p=0.01), but were otherwise similar with regard to tumor size, tumor grade, and race.
Genes Associated with Increased Recurrence in Triple Negative Disease
We evaluated the relationship between gene expression and recurrence in the 246 patients with TNBC. There were 6 genes significantly associated with recurrence (adjusted p-value < 0.05), including 1 gene for which increased expression was associated with increased recurrence, and 5 with decreased recurrence. In order to show the relationship between gene expression and recurrence, we show the hazard ratio per 
In order to further characterize the relationship between GRB7 expression and recurrence in TNBC, we evaluated this relationship as a continuous variable using a spline model for the log hazard ratio as shown in Figure 1 . GRB7 RNA expression ranged from a low of 2.4 to as high as 10 units, which corresponds to about a 190-fold difference in RNA expression between the highest and lowest values. There was a highly significant relationship between the risk of recurrence and GRB7 expression (p=0.001).
The median value of 6.5 was chosen for the additional categorical analyses, which falls on the maximal slope of the curve. The estimated hazard ratio for high versus low expression based on the median split was 2.24 (p=0.006). If tertile splits were used, the difference between the low and intermediate groups was not significant (HR 0.85, 95% CI 0.39,1.88), but was significant for high vs. intermediate is (HR 2.41, 95% CI 1.27, 4.59, p=0.007). Therefore, the median split was used to define GRB7 as a categorical variable in subsequent analyses. Higher GRB7 expression was also associated with significantly higher risk of recurrence in the subset of 60 patients with ER/PR-negative, HER2/neu positive disease (hazard ratio for high vs. low expression 1.75, 95% C.I. 1.02, 3.00, p=0.04).
Relationship Between GRB7 Expression and Clinical Variables
In order to evaluate the relationship between GRB7 expression and clinical variables, we compared the clinical characteristics of patients with high versus low expression levels (supplemental Table 1 ). There were no significant differences in any clinical characteristic examined between patients who exhibited high versus low GRB7 expression levels, except for fewer patients over 65 years of age with high GRB7 expression (3% vs. 10%, p=0.03).
Multivariate Analysis: Relationship Between GRB7 Expression and Recurrence
In order to evaluate the relationship between GRB7 expression and recurrence adjusted for clinicopathologic variables, Cox proportional hazards models were fit to examine the joint effects of factors on recurrence rates, as shown in Table 2 . The models included age, nodal status, centrally determined tumor grade, and tumor size. In Model I, which did not include GRB7 expression, features associated with an increased risk of recurrence included 1 positive axillary lymph node (versus none) and large tumor size (more than 2 cm). Model II added GRB7 as a continuous linear variable to Model I; GRB7 x +2 vs. x was used for the hazard ratio (corresponding to an approximately 4-fold increase in gene expression), where x is an arbitrary value of GRB7 (comparable to the analysis of Recurrence Score as continuous variable in the report by Paik et al, 13 ). In this model, GRB7 expression was a highly significant predictor for recurrence (hazard ratio 3.41, 95% CI 1.78, 6.53; p=0.002). Model III added GRB7 as a dichotomous variable (high vs. low, using the median split) to Model I. In this model, there was also a significant relationship between GRB7 expression and recurrence (hazard ratio 2.31, 95% CI 1.30, 4.11; p=0.004).
Pathway Analysis of Differentially Expressed Genes
Research. 
Validation in Other Datasets
We evaluated the relationship between GRB7 expression and outcomes in several publicly available datasets, which used various methods to examine gene expression.
With regard to prognosis, we found no relationship between GRB7 expression and recurrence in patients with node-negative breast cancer who received no adjuvant chemotherapy (excluding patients with high ERBB2 and ER expression) 19 , and in patients with basal breast cancer subtype with node-negative or positive disease (some of whom received adjuvant chemotherapy) (data not shown). 5, 20 With regard to prediction, GRB7 expression level was evaluated in 76 patients with TNBC treated with neoadjuvant sequential epirubicin and docetaxel-containing chemotherapy. 21 There was no significant difference in the proportion with pathologic complete response (pCR) who had an elevated GRB7 expression at or above the median compared with below the median (13 
DISCUSSION
We performed an exploratory analysis evaluating the relationship between recurrence and a panel of genes in 246 patients with stage I-III TNBC who received standard doxorubicin-containing chemotherapy and were followed for at least five years. evaluated for ER, PR, and HER2-expression by immunohistochemistry in a standardized and rigorous manner and confirmed to be triple negative.
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GRB7 was the only gene for which higher expression was found to be associated with a significantly elevated risk of recurrence, suggesting that GRB7 may serve as an important biomarker in TNBC, and that perhaps GRB7 or GRB7-dependent pathways may serve as therapeutic targets.
Similar to Oncotype DX Recurrence Score in ER-positive breast cancer, the relationship between GRB7 expression and recurrence was evident when evaluated as a continuous variable or dichotomous variable adjusted for other covariates, and the relative risk elevation was comparable. For example, a 50 unit increase in RS (which has a range of 0-100) was associated with a 2-8 fold increase (p<0.001) in risk of distant recurrence in ER-positive disease treated with tamoxifen in the B14 trial 25 , and 2.1-fold increase (p=0.06) in ER-positive disease treated with adjuvant chemotherapy plus tamoxifen in the E2197 trial 12 , whereas a 2 unit increase in GRB7 expression (range 2.4-8) was associated with a 3.4-fold increase (p=0.002) in the risk of recurrence in TNBC evaluated in this dataset. When evaluated in four other publicly available datasets, although GRB7 expression was not associated with recurrence in patients who received no adjuvant chemotherapy, median GRB7 expression levels were significantly higher in patients with TNBC who failed to achieve a pCR after preoperative anthracycline and taxane therapy.
Although there was no specific GRB7 expression threshold predictive of response in these relatively small neoadjuvant trials, the significantly higher median expression levels recurrence in the presence or absence of adjuvant chemotherapy 26 , providing additional independent evidence supporting our findings.
GRB7 belongs to a small family of mammalian SH2 domain adapter proteins that are known to interact with a number of receptor tyrosine kinases and signaling molecules (including HER1, HER2, and ephrin receptors), with the integrin signaling pathway, and with focal adhesion kinase (FAK). 27, 28 GRB7 shares sequence homology with the mig-10 gene of C. elegans, which is required for migration of embryonic neurons, suggesting an important role in cell motility.
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GRB7 is also included in the 21 gene signature in estrogen-receptor-positive disease 25 , and in the 512 intrinsic gene set 4 and PAM50 gene set 5 , indicating other evidence that is may be an important biomarker. GRB7 is located on the same amplicon as the erbB2 gene and thus usually coamplified in HER2/neu overexpressing breast cancers, and we confirmed that GRB7 expression levels were significantly lower in HER2/neu non-overexpressing tumors. Although GRB7 expression was correlated with ERBB2 expression within the TNBC group (r=0.70), GRB7 but not ERBB2 expression was significantly associated with recurrence in this population, supporting its role as a prognostic marker in this setting. Supporting its potential as a therapeutic target, several inhibitors of GRB7 have been developed, some of which have been shown to potentate the effects of cytotoxic therapy and trastuzumab. [30] [31] [32] [33] In addition, inhibitors of GRB7-dependent pathways such as FAK, lines to doxorubicin and docetaxel. 36 Taken together, these findings GRB7 as a key mediator of migration, invasion, colony growth and chemoresistance of TNBC, and suggest that in addition to serving as a prognostic or predictive biomarker, GRB7-dependent pathways may prove to be important therapeutic target in TNBC.
Although GRB7 was the only gene for which increased expression was associated with an increased risk of recurrence, increased expression of several other genes was found to be associated with a significantly lower risk of recurrence, including CD68, a macrophage antigen likely reflecting host cells infiltrating the tumor. CD68 is also one of Table 3 . These include inhibitors of aurora kinase B [37] [38] [39] , polo-like kinase 1 40, 41 , kinesin family member C1, checkpoint kinase 1 42 , and forkhead box M1. 43 The pathway analysis indicates that some of these proteins (encoded by their genes) may be particularly vulnerable targets because they serve as nodes for interaction or transcriptional effectors, including aurora kinase B (AURKB), increased risk of basal-like breast cancer [OR 2.0, 95% CI (1.1-3.8)]; they also showed that MYBL2 is involved in cell cycle control, and that its dysregulation contributes to increased sensitivity specifically to DNA topoisomerase II inhibitors. 44 There are several notable strengths of this analysis. First, this is one of the largest training sets specifically evaluating gene expression in a uniformly treated cohort of patients with TNBC; inadequate sample size is recognized as a major limitation of previous studies. 45 Second, the TNBC group was defined by standard IHC methods commonly used in clinical practice, but performed in a standardized and rigorous manner in a central lab. Third, we evaluated a limited panel of candidate genes that were rationally selected because of their known or postulated association with prognosis or response to chemotherapy rather than a genome wide approach, and used a standardized RT-PCR method that brings precision and large dynamic range. This offers the potential to reduce the likelihood of identifying falsely positive associations by enriching for candidate genes likely to be associated with recurrence, and provides confidence in assuring reproducibility of the identified genes and the method of measuring their expression. In addition, stringent statistical methods were used to control false discovery. 17 Some of the analyses were also adjusted for clinicopathologic variables in order to explore whether specific genes, such as GRB7, provided information beyond standard clinicopathologic measures. Lastly, we performed external validation in four independent data sets and confirmed that high GRB7 expression was associated with resistance to doxorubicin and taxane therapy, but did not provide prognostic information in the absence of systemic chemotherapy. There were also several limitations of this analysis. A fundamental premise of our study is that increased gene transcription, as reflected by RNA expression levels, may identify potential therapeutic targets, biomarkers predictive of clinical behavior or response to therapy, or both. However, altered transcription may reflect an effect rather than a cause of the malignant phenotype. In addition, searching for activating gene mutations, oncogenes, or inactivated tumor suppressor genes may be a more fruitful strategy for therapeutic targeting. 46 On the other hand, there is a clear precedent for effectively targeting pathways in breast cancer that are not associated with discernable activating mutations, as exemplified by antiestrogen therapy.
In conclusion, we identified several genes that are novel therapeutic targets in TNBC, and which may have potential clinical utility. Validation in preclinical systems will be required for drug development, and additional validation in other clinical datasets will be required for clinical application.
